TuHURA Biosciences Announces Its Release of Kintara’s Contingent Value Right (CVR) As Kintara’s REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone (PR Newswire))

TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, announced that Kintara’s REM-001 clinical trial of ten metastatic cutaneous breast cancer patients met its primary endpoint, demonstrating safety with signs of clinical efficacy following eight weeks of follow-up for such patients.

Pursuant to the terms of the Contingent Value Rights Agreement dated as of October 18, 2024, by and between TuHURA Biosciences, Inc. and the rights agent, Equiniti Trust Company, LLC (the “CVR Agreement”), as a result of the trial and the completion of the follow-up, the milestone required for the release of an aggregate of 1,539,958 shares of TuHURA common stock to legacy Kintara Therapeutics stockholders has been achieved.

Read more about TuHURA Biosciences Announces Its Release of Kintara’s Contingent Value Right (CVR) As Kintara’s REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone.